Stockscreener 앱 받기
3.89
1.77%
-0.07
전일 마감가:
$3.96
열려 있는:
$3.86
하루 거래량:
89,727
Relative Volume:
0.39
시가총액:
$93.64M
수익:
$52.29M
순이익/손실:
$-73.52M
주가수익비율:
-5.8939
EPS:
-0.66
순현금흐름:
$-100.45M
1주 성능:
+2.37%
1개월 성능:
-5.35%
6개월 성능:
-17.06%
1년 성능:
-23.12%
1일 변동 폭
$3.78
$4.025
1주일 범위
$3.615
$4.11
52주 변동 폭
$3.53
$8.82
Precision Biosciences Inc Stock (DTIL) Company Profile
명칭
Precision Biosciences Inc
전화
919-314-5512
주소
302 EAST PETTIGREW STREET, DURHAM, NC
Compare DTIL vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
3.89 | 95.32M | 52.29M | -73.52M | -100.45M | -0.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-10 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2024-04-30 | 개시 | Guggenheim | Buy |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-06-09 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2020-07-27 | 재개 | BTIG Research | Buy |
| 2020-04-03 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-03-05 | 개시 | Stifel | Buy |
| 2020-02-25 | 개시 | William Blair | Outperform |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-07-16 | 개시 | H.C. Wainwright | Buy |
| 2019-04-22 | 개시 | Barclays | Overweight |
| 2019-04-22 | 개시 | Goldman | Buy |
| 2019-04-22 | 개시 | JP Morgan | Overweight |
| 2019-04-22 | 개시 | Jefferies | Buy |
모두보기
Precision Biosciences Inc 주식(DTIL)의 최신 뉴스
Precision BioSciences receives U.S. FDA clearance of investigational new drug application for first-in-class PBgene-Dmd for treatment of Duchenne muscular dystrophy - marketscreener.com
Precision Biosciences’ PBGENE-DMD cleared to enter clinic - bioworld.com
Precision BioSciences Receives FDA Clearance for PBGENE-DMD Program - TradingView
Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy - Business Wire
Chart Watch: What is the long term forecast for Precision BioSciences Inc stockEarnings Performance Report & Long-Term Investment Growth Plans - baoquankhu1.vn
Aug Catalysts: Is Precision BioSciences Inc likely to announce a buybackMarket Risk Report & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Precision BioSciences, Inc. (NASDAQ:DTIL) Short Interest Update - MarketBeat
Aberdeen Group plc Acquires Significant Stake in Precision BioSciences Inc - GuruFocus
Aug Decliners: Can WRLD weather a recessionMarket Volume Summary & Weekly Watchlist of Top Performers - baoquankhu1.vn
Signal Recap: Is Precision BioSciences Inc likely to announce a buybackWeekly Trading Summary & Intraday High Probability Alerts - baoquankhu1.vn
Chart Watch: Should I average down on KDLY stock2025 Market Overview & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Precision BioSciences launches $75M stock and warrant offering - MSN
Aug Mood: What is DURECT Corporations book value per shareWatch List & Low Drawdown Momentum Ideas - baoquankhu1.vn
Michael Amoroso Sells 34,799 Shares of Precision BioSciences (NASDAQ:DTIL) Stock - MarketBeat
Precision BioSciences (NASDAQ:DTIL) Insider J. Jefferson Smith Sells 10,200 Shares - MarketBeat
Precision BioSciences (NASDAQ:DTIL) CFO Sells $61,308.39 in Stock - MarketBeat
Precision Biosciences CFO sells $61k in shares By Investing.com - Investing.com UK
Precision Biosciences chief research officer Smith sells $41k in shares By Investing.com - Investing.com Nigeria
Scimeca, Precision Bio general counsel, sells $35,681 in DTIL stock By Investing.com - Investing.com Canada
Precision Biosciences chief research officer Smith sells $41k in shares - Investing.com
Genome Editing Market Forecast to Reach $23.6 Billion by 2031 Registering 16.6% CAGR: Insights Into Technology and Investment Trends - GlobeNewswire Inc.
Precision BioSciences (NASDAQ:DTIL) Trading Down 3.8%Time to Sell? - MarketBeat
Guidance Update: Is Precision BioSciences Inc stock trending bullishIPO Watch & Pattern Based Trade Signal System - baoquankhu1.vn
Aug Levels: How does Precision BioSciences Inc perform in inflationary periods2025 Dividend Review & Fast Gain Swing Alerts - baoquankhu1.vn
Trend Recap: Will Precision BioSciences Inc stock benefit from green energy trends2025 Price Action Summary & Technical Pattern Based Signals - Bộ Nội Vụ
Precision BioSciences Highlights 2026 Gene Editing Priorities - TipRanks
Precision BioSciences advances gene editing programs with key milestones By Investing.com - Investing.com Nigeria
Aug Catalysts: Is Precision BioSciences Inc stock trending bullishPortfolio Value Summary & Detailed Earnings Play Strategies - baoquankhu1.vn
Precision BioSciences advances gene editing programs with key milestones - Investing.com
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy - Business Wire
Precede Biosciences Secures $83.5M in Total Financing to Scale Next-Generation Precision Diagnostics Platform - GlobeNewswire
Precision BioSciences Shares Surge Following FDA Rare Pediatric Disease Designation - MSN
Will Precision BioSciences Inc. stock outperform Nasdaq indexMarket Performance Recap & Detailed Earnings Play Alerts - ulpravda.ru
Can Precision BioSciences Inc. (PBS0) stock deliver strong annual returns2025 Short Interest & Accurate Buy Signal Alerts - Улправда
Can Precision BioSciences Inc. stock reach $100 price targetJuly 2025 Price Swings & Verified Swing Trading Watchlists - Улправда
Is Precision BioSciences Inc. stock a top pick in earnings seasonEarnings Performance Report & AI Driven Price Forecasts - Улправда
Will Precision BioSciences Inc. stock split again soon2025 Winners & Losers & Low Drawdown Investment Strategies - Улправда
How Precision BioSciences Inc. stock compares to market leadersWeekly Market Outlook & Smart Swing Trading Techniques - Улправда
Can Precision BioSciences Inc. stock hit analyst price targetsQuarterly Trade Review & Low Drawdown Investment Ideas - Улправда
Is Precision BioSciences Inc. (PBS0) stock a top hedge fund pickIPO Market Watch & Free High Yield Investment Strategies - Улправда
Precision BioSciences: Tiny Gene-Editing Stock Caught Between Deep Cuts and Big Optionality - AD HOC NEWS
Precision Bio's DMD Therapy Gets Rare Pediatric Status, But Stock Slides; Retail Crowd Sees ‘Good Risk-Reward’ - MSN
What drives Precision BioSciences Inc PBS0 stock priceSell Signals and Alerts & Low Cost Portfolio Tips - earlytimes.in
Sterling Tools Limited Ranks High in Smart Money TrackerFundamental Strength Indicators & Explosive Profit Growth - earlytimes.in
Aug Ideas: Is Precision BioSciences Inc stock a top pick in earnings season - moha.gov.vn
Short Interest in Precision BioSciences, Inc. (NASDAQ:DTIL) Expands By 27.4% - MarketBeat
Earnings Update: Is Precision BioSciences Inc stock a top pick in earnings seasonWeekly Earnings Recap & Consistent Profit Trading Strategies - Bộ Nội Vụ
Precision Biosciences Inc files for mixed shelf of up to $250 millionSEC filing - MarketScreener
Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026 (NASDAQ:DTIL) - Seeking Alpha
Will Precision BioSciences Inc. stock benefit from infrastructure spendingMarket Breadth Indicators & Investor Community Interactions - bollywoodhelpline.com
Can Precision BioSciences Inc. stock maintain operating marginsEarnings Volatility Patterns & Affordable Stock Picks - bollywoodhelpline.com
Precision Biosciences Inc (DTIL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Precision Biosciences Inc 주식 (DTIL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Scimeca Dario | General Counsel and Secretary |
Jan 20 '26 |
Option Exercise |
0.00 |
25,311 |
0 |
53,569 |
| Scimeca Dario | General Counsel and Secretary |
Jan 21 '26 |
Sale |
4.03 |
8,854 |
35,682 |
44,715 |
| Kelly John Alexander | Chief Financial Officer |
Jan 21 '26 |
Sale |
4.03 |
15,213 |
61,308 |
106,448 |
| SMITH J. JEFFERSON | Chief Research Officer |
Jan 21 '26 |
Sale |
4.03 |
10,200 |
41,106 |
110,184 |
1.12%
0.87%
자본화:
|
볼륨(24시간):